GLG News by Physicians who Treat Acne (US)

William FinkPresidentManaged Care Pharmacy Consultants, Inc

"Health Care Laws by Any Name Will Not Work"

June 15, 2011

You can name the health care laws "ObamaCare", "Palin Care", "Trump Care", "Huckabee Care", or any "Care" you want, but they will not work, because it is not the laws that are messed up it is the public that is messed up.

William FinkPresidentManaged Care Pharmacy Consultants, Inc

PBMs NOT ALWAYS THE BAD GUYS

May 11, 2011

There are many articles written by attorneys explaining how they can write contracts with the PBMs in order to save their clients a great deal of money.

William FinkPresidentManaged Care Pharmacy Consultants, Inc

Does the Teva Cephalon Deal have an unknown problem?

May 3, 2011

Analysis of:Teva to acquire Cephalon in 6.8 Billion Transaction | www.glgroup.com

Teva is embarking on a new and exciting future for its "Branded Business" Teva wants to obtain the "Dollars" from PROVIGIL. Provigil is a very expensive product for Narcolepsy. The price on this product was increased over 40% (approx) a few months ago. I am a clinical pharmacist , and manage pharmacy programs for HMOs and Self Insured Employer Groups. The time is coming when payors will not be able to afford medications with out a large increase in Employees out of pocket expenses.

Michael BainWound Care DirectorNewport Nursing and Rehabilitation

FDA issues safety signal on ALCL & breast implants

January 31, 2011

Analysis of:FDA issues safety signal on ALCL & breast implants | www.psnextra.org

http://www.psnextra.org/Articles/FDA-ACLC-Issue.htmlThere is a link between breast implants and anaplastic large cell lymphoma (ALCL).  This very rare tumor has almost no cases in the literature.  There appears that there might be an association between the two.

Jon StrasserAssistant Professor of Radiation OncologyTHOMAS JEFFERSON UNIVERSITY

Particle Beam Technology - Costly and a limited utility

October 26, 2009

Analysis of:Particle Beam Radiation Therapy published by AHRQ | effectivehealthcare.ahrq.gov

Over the last several years, there has been an increased interest in the US in particle beam therapy as the costs have come down and large manufacturers have become more efficient in installing these centers. In addition, private companies have made a business model of building proton centers - mostly by treating prostate cancer.Protons are incredibly useful in specific diseases - ie ocular melanoma, pediatric cancers, but are too costly without proven benefit for our health care system.

Jeffrey WeinbergDirector of Clinical Research - DermatologyST LUKE'S-ROOSEVELT HOSPITAL CENTER

Starpharma gets US patent for use of VivaGel for protection against STIs

September 29, 2009

Analysis of:Starpharma gets US patent for use of VivaGel for protection against STIs | www.pharmabiz.com

Starpharma's lead product, is a vaginal microbicide gel under development for the prevention of sexually transmitted infections (STIs), including genital herpes and HIV infection. The VivaGel® product concept is designed to offer a safe, convenient and affordable means for women to protect themselves from infection with genital herpes and HIV during sex. Surveys show that there is substantial demand in North America and Europe for such a product with an estimated billion dollar market for STI prevention products in the developed world.

Jeffrey WeinbergDirector of Clinical Research - DermatologyST LUKE'S-ROOSEVELT HOSPITAL CENTER

Stelara new Option for Psoriasis

September 26, 2009

Analysis of:Stelara Approved to Treat Moderate to Severe Plaque Psoriasis in Adults | www.webmd.com

The FDA approved Stelara based on three studies of 2,266 patients who either got shots of Stelara or a placebo. Patients who got Stelara were more likely to achieve the studies' benchmark for reduction in psoriasis.In a news release, the FDA notes that because Stelara reduces the immune system's ability to fight infections, the product poses a risk of infection. "Serious infections have been reported in patients receiving the product and some of them have led to hospitalization. These infections were caused by viruses, fungi, or bacteria that have spread throughout the body. There may also be an increased risk of developing cancer," the FDA states.

William FinkPresidentManaged Care Pharmacy Consultants, Inc

Dangers of Methadone Usage

August 28, 2008

Analysis of:Dr. Mark Yergin testifies to Congress | www.nytimes.com

Doctors must be educated on the correct use of Methadone if unnecessary deaths are to be avoided.

William FinkPresidentManaged Care Pharmacy Consultants, Inc

Trends for Chronic Kidney Disease (CKD)

June 26, 2008

Analysis of:Resource Article: “Chronic Kidney Disease Prevalence Increases, Awareness Remains Low,” Drug Benefit Trends (vol. 20, no. 5, May 2008) | jama.ama-assn.org

There will be an increased use of costly diaylsis, especially among those people 70 years or older.  One would think that there would be a greater awareness of a disease consting $31 billion dollars a year.  However, this does not seem to be the case.

Jeffrey WeinbergDirector of Clinical Research - DermatologyST LUKE'S-ROOSEVELT HOSPITAL CENTER

Issues with Ustekinumab

June 23, 2008

Analysis of:Positive news on J&J's ustekinumab diminished by safety concerns - analysts | www.tradingmarkets.com

On Tuesday, the FDA's Dermatologic and Ophthalmic Drug Advisory Panel voted unanimously to approve the use of the injectable drug for the treatment of plaque psoriasis, a severe skin disease. As the FDA usually follows the recommendations of its advisory panels when reviewing new drugs for approval, it is anticipated that the regulatory body will approve the drug in the fourth quarter, analysts said. But concerns over the drug's carcinogenic potential and the panel's recommendation that the drug be administered only by a physician and not directly by the patient could diminish enthusiasm over ustekinumab and lessen the drug's potential market share.

Page : 12345678910Next1 to 10 of 93